secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001628280-24-020009
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology Q1 net loss narrows to $65.3M; CFO stepping down; pipeline catalysts ahead
--------------------------------------------------------------------------------

- Net loss of $65.3M ($0.48 loss per share) vs $140.9M ($1.06) in Q1 2023; revenue $56.4M down 10.5% YoY.
- Cash, equivalents & investments $1.51B, down $118M in Q1; FY2024 R&D+SG&A guidance reaffirmed $650-680M.
- CFO Sung Lee stepping down effective May 3; successor search initiated.
- SOLSTICE hepatitis delta late-breaker abstract accepted at EASL June; 24-week data expected Q4 2024.
- MARCH hepatitis B data and HIV VIR-1388 immunogenicity data expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828024020009/0001628280-24-020009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828024020009/vir-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-020009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer